~~<i id='C28A82037B'><strike id='C28A82037B'><tt id='C28A82037B'><pre id='C28A82037B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

Wikipedia

author：leisure time 2025-10-02 23:31:54 - browse：7912

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： At Orexo, a ‘turning point’ for everything but digital health

hotspot

leisure time

Wikipedia

hotspot

focus

knowledge

AdobeVerveTherapeuticssaidMondaythatithadreceivedclearancefromtheFoodandDrugAdministrationtoconducta

WSS

AI can’t replace a physician’s gut feeling

AI can’t replace a physician’s gut feeling

UnitedHealth, Optum discontinue NaviHealth name

Custom gene therapy hints at new path for rare disease treatments

Roche drug slashes death risk in early

A public scorecard can help hold safety

leisure time

Wikipedia

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

FDA approves RSV monoclonal antibody for infants, toddlers

In age of alternative facts, a scholarly course on calling out crap

Cosmetics set for new safety regulation. Why the industry is on board

Duchenne breakthrough therapy leaves behind pioneering families

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Psychedelics group wrestles with new pharma identity

Google and Epic fight stronger regulation of AI in health care

Heart attack and stroke risk calculators need revising

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

leisure time

Biden tests positive for Covid

FDA clears Verve to begin U.S. study of gene

Cassava Sciences’ Alzheimer’s clinical trials should be halted

At Orexo, a ‘turning point’ for everything but digital health

Group opposing PBM reform sets lobbying record

Medicare to cover more brain scans for Alzheimer’s patients

Wikipedia

hotspot

focus

knowledge